Financial Data and Key Metrics Changes - Full-year revenue growth of 6% and adjusted diluted earnings per share growth of 7% were reported, with free cash flow of $2.1 billion, representing about 100% of adjusted net income [5][21] - Fourth quarter revenue was $4.364 billion, up 10.3% on a reported basis and 8.1% at constant currency, with adjusted EBITDA increasing by 5% year-over-year [21][23] - Full-year revenue reached $16.31 billion, up 5.9% reported and 4.8% at constant currency [22] Business Line Data and Key Metrics Changes - Technology Analytics Solutions revenue for Q4 was $1.821 billion, up 9.8% reported and 7.1% at constant currency [21] - R&D Solutions revenue for Q4 was $2.333 billion, up 9.1% reported and 8.2% at constant currency [21] - Contract Sales and Medical Solutions (CSMS) revenue for Q4 was $210 million, increased 18.6% reported and 15.3% at constant currency [21] Market Data and Key Metrics Changes - Net bookings for R&D Solutions totaled over $2.7 billion, growing 7% year-over-year, with a net book-to-bill ratio of 1.18 [9][10] - Backlog reached a record $32.7 billion at the end of the quarter, growing 5.3% compared to the prior year [10][24] - EBP funding was strong in Q4, reaching $33 billion according to BioWorld [11] Company Strategy and Development Direction - The company is focusing on simplifying its organization to enhance collaboration and efficiency, aligning teams with the evolving operating model [15] - A strategic collaboration with Amazon Web Services was announced to accelerate digital transformation in the industry [11] - The company is investing in AI capabilities and has deployed over 150 AI agents across various use cases [38][41] Management's Comments on Operating Environment and Future Outlook - Management noted that the macroeconomic environment had stabilized somewhat, leading to improved demand indicators and increased funding [5][6] - The company expects revenue for 2026 to be between $17.15 billion and $17.35 billion, with adjusted EBITDA guidance of $3.975 billion to $4.025 billion [26][27] - Management expressed confidence in the resilience of the business and the potential for AI to enhance operations rather than disrupt them [62][64] Other Important Information - The company was recognized by Everest Group for AI leadership, being the only clinical research organization to receive the top ranking for generative AI leadership in life sciences [12] - The CFO, Ron Bruehlman, is transitioning to a senior advisory role after this earnings call [17][18] Q&A Session Summary Question: Concerns about AI disrupting established businesses - Management clarified that AI is viewed as an opportunity rather than a challenge, emphasizing the company's proprietary data and domain expertise as key differentiators [32][34][41] Question: Value and driver of the Cedar Gate acquisition - The acquisition is expected to enhance patient outcomes and provide analytics to payers, with projected revenue of approximately $125 million in 2024 [46][48] Question: Impact of AI on trial efficiency and demand for services - Management indicated that large pharma's use of AI for trial efficiency does not negatively impact demand for their services, and they expect to continue growing and gaining market share [70][72] Question: Margin trajectory and productivity sharing with clients - Management acknowledged that while margins were slightly down, productivity gains are shared with clients, and pass-through growth was a significant driver of gross margin [76][84]

Financial Data and Key Metrics Changes - Full-year revenue growth of 6% and adjusted diluted earnings per share growth of 7% were reported, with free cash flow of $2.1 billion, representing about 100% of adjusted net income [5][21] - Fourth quarter revenue was $4,364 million, up 10.3% on a reported basis and 8.1% at constant currency, with adjusted EBITDA increasing by 5% year-over-year [21][23] - Full-year revenue reached $16.31 billion, up 5.9% reported and 4.8% at constant currency [22] Business Line Data and Key Metrics Changes - Technology Analytics Solutions revenue for Q4 was $1,821 million, up 9.8% reported and 7.1% at constant currency [21] - R&D Solutions revenue for Q4 was $2,333 million, up 9.1% reported and 8.2% at constant currency [21] - Contract Sales and Medical Solutions (CSMS) revenue for Q4 was $210 million, increased 18.6% reported and 15.3% at constant currency [21] Market Data and Key Metrics Changes - Net bookings for R&D Solutions totaled over $2.7 billion, growing 7% year-over-year, with a net book-to-bill ratio of 1.18 [10] - Backlog reached a record of $32.7 billion at the end of the quarter, growing 5.3% compared to the prior year [10][24] - Encouragingly, EVP funding was strong in Q4, reaching $33 billion according to Bioworld [11] Company Strategy and Development Direction - The company is simplifying its organization in 2026 to strengthen collaboration and enhance efficiency, aligning teams with the evolving operating model [15] - A strategic collaboration with Amazon Web Services was announced to accelerate digital transformation in the industry [11] - The company is focusing on AI-driven innovations and has deployed over 150 AI agents across various use cases [38] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the demand environment stabilizing, with improved customer trends and solid execution from sales teams [5][10] - The company anticipates revenue for 2026 to be between $17.15 billion and $17.35 billion, with adjusted EBITDA guidance of $3.975 billion to $4.025 billion [26][27] - Management emphasized that AI is viewed as an enabling technology rather than a threat, enhancing productivity and efficiency [41][62] Other Important Information - The company was recognized by Everest Group for AI leadership, being the only clinical research organization to receive the number one ranking for generative AI leadership in life sciences [12] - The last earnings call for CFO Ron Bruehlman was noted, who will transition to a senior advisory role [17][18] Q&A Session Summary Question: Concerns about AI disrupting established businesses - Management clarified that AI is seen as an opportunity rather than a challenge, emphasizing the proprietary data and domain expertise that differentiate the company [32][34][41] Question: Value and driver of the Cedar Gate acquisition - The acquisition is expected to enhance patient outcomes and provide analytics to payers, with projected revenue of about $140 million in 2025 [46][48] Question: Impact of AI on trial efficiency and demand for services - Management stated that AI will improve trial efficiency but does not foresee a reduction in the number of trials conducted by large pharma [70][72] Question: Margin trajectory and pass-through growth - Management indicated that pass-through growth was a significant driver of gross margin, with expectations for flat overall EBITDA margins in the upcoming year [76][84]

Financial Data and Key Metrics Changes - The company reported a full-year revenue growth of 6% and adjusted diluted earnings per share growth of 7% for 2025, with free cash flow of $2.1 billion, representing about 100% of adjusted net income [4][24] - Fourth quarter revenue was $4,364 million, up 10.3% on a reported basis and 8.1% at constant currency, with adjusted diluted EPS of $3.42, an increase of 9.6% year-over-year [20][23] - Full-year revenue reached $16.31 billion, up 5.9% reported and 4.8% at constant currency [21] Business Line Data and Key Metrics Changes - Technology Analytics Solutions revenue for Q4 was $1,821 million, up 9.8% reported and 7.1% at constant currency [20] - R&D Solutions revenue for Q4 was $2,333 million, up 9.1% reported and 8.2% at constant currency [20] - Contract Sales and Medical Solutions (CSMS) revenue for Q4 was $210 million, an increase of 18.6% reported and 15.3% at constant currency [20] Market Data and Key Metrics Changes - The backlog reached a new record of $32.7 billion at the end of Q4, growing 5.3% compared to the prior year [9][23] - Qualified pipeline was about 10% higher year-over-year, with double-digit growth in RFP flow across all segments [9] Company Strategy and Development Direction - The company is focusing on simplifying its organization into two reporting segments: Commercial Solutions and R&D Solutions, to better align with evolving market demands [14][15] - A strategic collaboration with Amazon Web Services was announced to accelerate digital transformation in the industry [10] - The company is investing in AI-driven innovations and has deployed over 150 AI agents across various use cases [37][40] Management's Comments on Operating Environment and Future Outlook - Management noted that the macroeconomic environment led to slower customer decision-making but indicated that demand indicators became more favorable as the year progressed [4][5] - The company expects revenue for 2026 to be between $17.15 billion and $17.35 billion, with adjusted EBITDA guidance of $3.975 billion to $4.025 billion [25][26] Other Important Information - The company was recognized for its AI leadership, being ranked number one for generative AI leadership in life sciences by Everest Group [11] - The CFO, Ron Bruehlman, is transitioning to a senior advisory role after a long tenure [16][17] Q&A Session Summary Question: Concerns about AI disrupting established businesses - Management clarified that AI is viewed as an opportunity rather than a challenge, emphasizing the company's proprietary data and domain expertise as key differentiators [31][32][40] Question: Value and driver of the Cedar Gate acquisition - The acquisition is expected to enhance the company's payer provider analytics capabilities, with Cedar Gate contributing approximately $140 million in revenue and $36-37 million in adjusted EBITDA for 2025 [46][47] Question: Impact of AI on trial efficiency and demand dynamics - Management stated that AI is expected to improve trial efficiency but does not foresee a reduction in the number of trials conducted by large pharma clients [68][70]

Financial Data and Key Metrics Changes - Revenue for Q2 2025 was $603.3 million, representing a year-over-year increase of 14.2% and 13.8% on a constant currency basis [9][10] - EBITDA for Q2 2025 was $130.5 million, an increase of 16.2% compared to $112.3 million in Q2 2024, with an EBITDA margin of 21.6% [11][12] - Net income for Q2 2025 was $90.3 million, a 2.2% increase from $88.4 million in the prior year [12] Business Line Data and Key Metrics Changes - Net new business awards entering backlog in Q2 increased by 12.6% year-over-year to $620.5 million, resulting in a net book-to-bill ratio of 1.03 [9] - Ending backlog as of June 30, 2025, was approximately $2.9 billion, a decrease of 1.8% from the prior year [9] Market Data and Key Metrics Changes - The funding environment has stabilized and improved, allowing most clients with ongoing studies to secure sufficient funding [8] - The company anticipates a shift in business towards faster-burning therapeutic areas, which have a higher concentration of reimbursable costs [14] Company Strategy and Development Direction - The company raised its revenue guidance for 2025 by $280 million at the midpoint, now expecting total revenue in the range of $2.42 billion to $2.52 billion [14] - The strategy includes focusing on faster-burning therapeutic areas and improving operational efficiency to enhance productivity [10][14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about accelerating revenue in the second half of the year due to improved funding, fewer cancellations, and rapid project start-ups [8] - There is a cautious outlook regarding potential future cancellations, which could impact 2026 revenue growth [29][30] Other Important Information - The company repurchased approximately 1.75 million shares for $518.5 million in Q2 2025, with $826.3 million remaining under the share repurchase authorization program [13] - The effective tax rate for 2025 is expected to be between 18.5% and 19% [14] Q&A Session Summary Question: What are the booking expectations for the second half? - Management expects bookings to increase, with a reasonable chance of achieving a book-to-bill ratio above 1.15, depending on cancellation rates [18] Question: Can you provide information on cancellations? - Cancellations were down across the portfolio, with rates lower than historical averages, contributing to better-than-expected performance [19] Question: How does the increased guidance break down between pass-through and direct revenue? - The increase is largely due to accelerated reimbursable cost activity, but there is also improved productivity from existing staff [24] Question: What is the outlook for funding and demand? - Management is cautious about the weak funding environment but has visibility into awarded projects that should support bookings [28][29] Question: What characterized the win rate this quarter? - The win rate was lower due to the loss of a few large projects, but overall decisions increased, leading to good new awards [46][52] Question: What is the expected hiring trend for the second half? - The company anticipates accelerated hiring in the second half, aiming for mid to upper single-digit growth in headcount [82][101]